Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase-producing Enterobacterales Undergoing Liver Transplantation: a Stepped Wedge Cluster Randomization Trial

This is a multicenter stepped-wedge cluster randomized trial, conducted over a 2-year period at three hospitals. The trial is structured into four phases, each lasting six months. During phase 1 (pre-rollout), all hospitals will use standard antibiotic prophylaxis for all patients. In each of phases 2 to 4, one hospital will switch to targeted antibiotic prophylaxis, so that by phase 4 all hospitals will be using it. The order in which hospitals switch is determined by computer-generated randomization performed centrally by an independent statistician, ensuring each hospital has an equal chance of switching at any given phase and minimizing selection bias.
The goal of this clinical trial is to learn whether targeted antibiotic prophylaxis works better than standard antibiotic prophylaxis at preventing infections in liver transplant patients who carry resistant bacteria called CPE (carbapenemase-producing Enterobacterales). It will also learn about the effects of these antibiotics on gut bacteria.
The main questions it aims to answer are:
* Does targeted antibiotic prophylaxis reduce the number of CPE infections occurring in the first two weeks after liver transplant, compared to standard prophylaxis?
* How do targeted and standard antibiotic prophylaxis affect the gut microbiome after transplant?
* Is there a link between achieving optimal antibiotic blood levels and the risk of developing an infection after transplant?
Researchers will compare targeted antibiotic prophylaxis (chosen based on the specific bacteria each patient carries) to standard antibiotic prophylaxis (used routinely at each hospital) to see which approach better prevents infection.
This study does not involve the administration of any drugs or instrumental examinations beyond those already part of standard clinical care at each center. However, additional blood tests will be performed by collecting one extra blood sample (and a bile sample, if the patient has a Kehr's tube, which is a drain placed in the bile duct after surgery) during blood draws already scheduled as part of routine clinical practice, in order to measure drug levels in the blood. Stool samples will also be collected specifically for the study to investigate the gut microbiome.

开始日期2026-10-01

申办/合作机构

IRCCS Azienda Ospedaliero-Universitaria di Bologna

NCT07478484

/ Recruiting临床4期IIT

A Clinical Study on Sequential Infusion Versus Concomitant Infusion of Ceftazidime-avibactam Combined With Aztreonam for the Treatment of Metallo-β-lactamase-producing Carbapenem-resistant Gram-negative Bacterial Infections.

Metallo-β-lactamase-producing carbapenem-resistant Gram-negative bacteria (MBL-CR-GNB), due to their capacity to hydrolyze almost all β-lactam antibiotics, have become a critical global threat in antimicrobial resistance. Current novel β-lactamase inhibitors (e.g., avibactam, relebactam, vaborbactam) only inhibit serine enzymes and are ineffective against metallo-β-lactamases (MBL), severely limiting clinical treatment options. Aztreonam (ATM) is inherently stable against MBL, while avibactam (AVI) inhibits co-produced serine β-lactamases (e.g., KPC, OXA-48). Their combination achieves complementary synergistic antibacterial effects. The ceftazidime-avibactam plus aztreonam (CZA+ATM) regimen, operating via the mechanism of "avibactam protecting aztreonam", has demonstrated synergistic bactericidal activity against NDM, VIM, IMP and other MBL-producers in multiple real-world and clinical studies, significantly reducing infection-related mortality.However, although current domestic and international guidelines recommend the CZA+ATM combination for MBL infections, there is no consensus on optimal infusion strategies. Based on the above, this study hypothesizes that in patients with complicated infections caused by MBL-producing CR-GNB, different infusion modalities of ceftazidime-avibactam combined with aztreonam-concomitant infusion versus sequential infusion-will show no significant differences in PK/PD target attainment rates, clinical cure rates, microbiological eradication rates, or all-cause mortality, without increasing the risk of adverse events.

开始日期2026-03-31

申办/合作机构

常州市第二人民医院

CTIS2024-516232-10-00

/ Not yet recruiting临床4期IIT

Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.

开始日期2025-12-01

申办/合作机构

Centre Hospitalier Universitaire de Nimes

100 项与氨曲南相关的临床结果

登录后查看更多信息

100 项与氨曲南相关的转化医学

登录后查看更多信息

100 项与氨曲南相关的专利（医药）

登录后查看更多信息

9,348

项与氨曲南相关的文献（医药）

2026-12-31·Emerging Microbes & Infections

Spread of carbapenemase-producing Serratia spp. in France from 2016 to 2024: a comparative genomic study

Article

作者: Jousset, Agnès B. ; Emeraud, Cécile ; Bonnin, Rémy A. ; Larouy-Maumus, Gerald ; Dortet, Laurent ; Ouacel, Kenza ; Rezzoug, Inès ; Bernabeu, Sandrine ; Birer, Aurelien

Carbapenemase-producing Serratia spp. are increasingly implicated in healthcare-associated infections. This study aimed to characterize the genetic diversity, resistance mechanisms, and susceptibility to last resort antimicrobials of carbapenem-resistant Serratia spp. in France. From 2016 to 2024, 193 carbapenemase-producing Serratia spp. from France were investigated. WGS enabled species identification, MLST typing, resistome characterization and phylogenetic analysis. Antimicrobial susceptibility was assessed by broth microdilution, focusing on last resort antimicrobials. Intrinsic resistance to polymyxins was explored by genomic analysis and lipid A mass spectrometry. S. sarumanii (54%) and S. nevei (41%) dominated the epidemiology while no S. marcescens was identified. The most prevalent carbapenemases were OXA-48-like (56%), NDM (25%), IMP (8%), and VIM (7%). MLST identified 67 sequence types (ST) with 42% of the isolates belonging to four high-risk clones: ST-601, ST-298, ST-477, ST-600 and ST-474. β-lactamse susceptibility was low, but aztreonam-avibactam remained highly active (98%). Intrinsic resistance to polymyxin did not result from lipid A modifications as reported for Proteae. In France, carbapenemase-producing Serratia spp. were dominated by S. sarumanii and S. nevei. The absence of S. marcescens, the genus leader, highlighted the need to update the MALDI-TOF database. This study highlights Serratia as an underestimated reservoir of multidrug resistance.

2026-12-01·MOLECULAR BIOLOGY REPORTS

Prevalence of quorum sensing luxS gene in multidrug resistant uropathogens

Article

作者: Kotturu, Sandeep Kumar ; Ghosh, Soham ; Pradhan, Shilpa ; Lakshmi, Swarajya ; Mukhopadhyay, Sangita

BACKGROUND:

The increasing prevalence of antimicrobial resistance (AMR) among urinary tract infections (UTIs) is making clinical management challenging. Biofilm formation is a key mechanism contributing to antibiotic resistance in uropathogens. Quorum sensing is known to regulate several bacterial processes like bioluminescence, virulence, and biofilm formation which is known to play a role in the development of drug resistance. Out of three major quorum sensing systems, luxS/AI-2 is a universal system used by both Gram-positive and Gram-negative bacteria.

METHODS:

Community-acquired AMR UTI isolates were analyzed for bacterial species distribution and antibiotic susceptibility patterns. Phenotypic biofilm formation was assessed using Congo Red Agar (CRA) method. The presence of luxS gene, associated with the AI-2 quorum sensing system, was determined by polymerase chain reaction (PCR).

RESULTS:

Eight different bacterial species were identified, with Escherichia coli (44.1%) being the most prevalent, followed by Klebsiella spp. (27.9%). More than 90% of the isolates were resistant to at least 3 antibiotics and resistance to ampicillin was most common (67.6%), followed by cefazolin (54.4%), amoxyclav (53.4%), aztreonam (52.9%), and ciprofloxacin (48.52%). Phenotypic biofilm formation was observed in 35.29% of the AMR isolates which produced characteristic black colonies. However, luxS gene was detected in 91.17% of these AMR isolates.

CONCLUSION:

Higher prevalence of luxS gene in AMR isolates indicate a strong association of quorum sensing potential with development of multidrug resistance. Targeting quorum sensing pathways may represent potential adjunct therapy alongside antibiotics for efficient clinical management of multidrug resistant UTI cases.

2026-12-01·MOLECULAR BIOLOGY REPORTS

High prevalence and co-existence of SHV and CTX-M genes in extensively drug-resistant (XDR) Gram-negative bacteria isolated from hospital settings in Faisalabad District, Pakistan

Article

作者: Shaukat, Amir ; Duarte, Tania Da Silva ; Sattar, Azfar ; Blaskovich, Mark A T ; Zuegg, Johannes ; Ahmad, Zaheer ; Ali, Aamir ; Sarwar, Yasra ; Shehzad, Khurram ; Abbas, Umair ; Sajjad, Huma

BACKGROUND: Hospital-acquired infections (HAIs) associated with increasing antimicrobial resistance (AMR) are becoming a global health challenge, causing AMR spread and a serious health threat. This study was designed to evaluate the phenotypic and genotypic status of AMR in Gram-negative HAI-associated bacteria, to gain a current insight into the local settings. METHODS AND RESULTS: Kirby-Bauer method and Double Disc Synergy Test were used for phenotypic assessment of AMR and extended-spectrum β-lactamase (ESBL) producers, respectively. Genes encoding antimicrobial resistance, ESBLs, and carbapenemases were identified by PCR followed by Sanger sequencing. Among 102 HAI samples, 62 were Gram-negative, identified as Escherichia coli (E. coli) (42.2%), Klebsiella pneumoniae (K. pneumoniae) (21.1%), and Pseudomonas aeruginosa (P. aeruginosa) (6.6%) by PCR. All K. pneumoniae and (95%) E. coli isolates exhibited multidrug resistance. K. pneumoniae isolates (95%) showed resistance against ceftazidime, cefotaxime, ceftriaxone, and aztreonam, and (89%) isolates were resistant to amoxicillin-clavulanic acid, ofloxacin, and cefepime (E. coli isolates (84%), (84%), (78%), (76%), (76%), and (73%) were resistant against cefotaxime, ceftriaxone, aztreonam, ceftazidime, doripenem, and colistin, respectively. Genotypically, the mcr-2 gene was detected in 5% K. pneumoniae isolates. Phenotypically, 63% isolates were identified as ESBL producers with high genetic prevalence of SHV-12 (78.9%) and SHV-1 (57.8%) in K. pneumoniae and CTX-M1 (60.5%) in E. coli. Notably, one K. pneumoniae isolate harbored all class-A ESBL genes, which is a novel finding. Co-existence of CTX-M1 + SHV-1 + TEM-1, SHV-1 + SHV-12 + TEM-1, and CTX-M1 + CTX-M15 + TEM-1 genes was dominant. CONCLUSION: The HAIs caused by extensively drug-resistant and ESBL-producing K. pneumoniae and E. coli were dominant, with less prevalence of moderately drug-resistant Pseudomonas isolates.

252

项与氨曲南相关的新闻（医药）

2026-08-10

·今日头条

创新药全线爆发！9 成药企纯蹭热点，这 8 家手握百亿长单才是真龙头今天 A 股创新药直接杀疯了，股价创历史新高的公司仅有11家，药企就占据了5家。百花医药五连板、百普赛斯20cm二连板，哈药股份秒板封单超50万手，但狂欢之下，真正有技术、有订单、有全球竞争力的，翻遍A股也就八家。今天A

创新药全线爆发！9 成药企纯蹭热点，这 8 家手握百亿长单才是真龙头今天 A 股创新药直接杀疯了，股价创历史新高的公司仅有11家，药企就占据了5家。百花医药五连板、百普赛斯20cm二连板，哈药股份秒板封单超50万手，但狂欢之下，真正有技术、有订单、有全球竞争力的，翻遍A股也就八家。今天AI 板块高位分歧资金集体高低切换，创新药板块逆势走强，机构扎堆调研百济神州，政策、业绩、资金三重利好扎堆发酵。但很多散户一看见 “ADC、创新药” 几个字就闭眼冲，踩坑踩得头破血流。目前市场上90% 医药股全是空壳概念，手里无核心管线、无落地产能，医院订单寥寥无几，千万别追高接盘！真正能穿越行情的创新药企业，三大硬标准缺一不可：独家自研新药、规模化生产产能、锁定两三年的大额长期供货订单。今天帮大家深度复盘筛选出，创新药的八强龙头公司，越往后订单体量越大，第一名更是断层领先。第8名：石药景峰，11 亿在手订单，排产至 2027 年底。石药集团，公司手握纳米制剂、玉冠丰两大独家研发平台，榄香烯、玻璃酸钠院内集采持续放量，一边自产特色抗肿瘤长效制剂，一边承接药企 CDMO 代工，院内制剂 + 外包代工双线增收，订单常年饱满。第7名：海南海药，手握 15 亿锁定订单，供货周期直达 2027 年。海南海药股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是注射用头孢西丁钠、注射用头孢唑肟钠、注射用美罗培南、注射用氨曲南、注射用头孢呋辛钠、注射用头孢曲松钠、盐酸米诺环素胶囊、头孢克洛颗粒、头孢克洛干混悬剂等公司走差异化路线，肝纤维化、神经领域拥有独家首创创新药，核心产品氟非尼酮获评突破性治疗品种。抗癫痫新药同步出海洽谈合作，肠胃康抗感染制剂铺满全国大小医院，院内长期采购协议稳稳兜底，属于冷门细分赛道隐形实力派。第6名：荣昌生物，45 亿大额订单交付到 2027 年末，国产稀缺双独家药企。荣昌生物制药(烟台），公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC278、RC288。公司自研 ADC 药物、红斑狼疮自免新药双王牌在手，同赛道国内竞品极少，核心 ADC 完成重磅海外授权，海内外医院终端采购持续放量，海外药企合作订单不断兑现，自免赛道稀缺标的。第5名：科伦药业，68 亿订单撑到 2027 上半年，ADC 管线孵化之王。四川科伦药业，公司依靠成熟制剂稳定现金流，疯狂孵化差异化 ADC 管线，旗下科伦博泰多次对外授权新药，海外里程碑收益持续落袋。肿瘤靶向药顺利进医保集采放量，海内外药企管线合作源源不断，长期订单稳定释放。第4名：凯莱英，99 亿框架订单覆盖 2026 至 2028 年，多肽、ADC 高端 CDMO 稀缺龙头。凯莱英医药集团，公司手握寡核苷酸、大分子偶联高壁垒独家工艺，深度绑定全球跨国药企，多款重磅新药签订长期锁产协议，海外大额储备订单充足，CXO 细分赛道硬核心。第3名：百济神州，126 亿供货订单铺满 2026-2028 年，国产新药全球化标杆。百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是抗肿瘤类药物。上周单家接待 207 家机构调研，关注度直接拉满。搭建完整全球商业化团队，多款创新药在欧美多国获批上市，海外营收占比行业顶尖，全球医疗机构全部锁定长期供货，国产新药出海第一梯队。第2名：恒瑞医药，398 亿在手订单断层行业第一，排期直接干到 2029 年。国内全品类综合创新药标杆，手握多款自主一类新药，多条 ADC 管线同步推进，频繁达成海外大额合作。国内各级医院核心供货企业，海内外长单源源不断，研发、商业化、产能三线无短板，稳稳坐稳创新药龙头王座。第1名：药明康德，590 亿在手订单排到 2027 年三季度。无锡药明康德新药开发股份有限公司的主营业务是为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务。公司的主要产品是化学业务、测试业务、生物学业务、其他业务。公司是全球独一份全链条 CRDMO 龙头。药物发现、临床前研究、临床试验、原料药生产一条龙全覆盖，服务全球数千家药企，ADC、GLP、细胞治疗项目批量落地。刚落地海外司法利好，半年报业绩大超预期，上调全年营收指引，全球长期研发订单持续扩容，业绩弹性拉满。给大家划重点：近日创新药大涨，但板块内部分化极端！那些纯蹭概念、零大额长单的小票，上涨全靠短线游资炒作；而上面八强企业，订单全部锁定未来 2-3 年业绩，就算市场短期震荡，营收利润也有实打实兜底。以上内容仅供参考，不构成任何投资建议 #创新药行情# #创新药指数# #今日复盘# #今日A股# #A股# #股市分析# #股市点评#

2026-08-10

·今日头条

创新药全线爆发！9 成药企纯蹭热点，这 8 家手握百亿长单才是真龙头

今天 A 股创新药直接杀疯了，股价创历史新高的公司仅有11家，药企就占据了5家。百花医药五连板、百普赛斯20cm二连板，哈药股份秒板封单超50万手，但狂欢之下，真正有技术、有订单、有全球竞争力的，翻遍A股也就八家。今天AI 板块高位分歧资金集体高低切换，创新药板块逆势走强，机构扎堆调研百济神州，政策、业绩、资金三重利好扎堆发酵。但很多散户一看见 “ADC、创新药” 几个字就闭眼冲，踩坑踩得头破血流。目前市场上 90% 医药股全是空壳概念，手里无核心管线、无落地产能，医院订单寥寥无几，千万别追高接盘！真正能穿越行情的创新药企业，三大硬标准缺一不可：独家自研新药、规模化生产产能、锁定两三年的大额长期供货订单。今天九九筛掉所有蹭概念的小票，帮大家深度复盘筛选出，创新药的八强龙头公司，越往后订单体量越大，第一名更是断层领先。第8名：石药景峰，11 亿在手订单，排产至 2027 年底。石药集团湖南景峰医药股份有限公司的主营业务是医药产品的研发、制造与销售。公司的主要产品是心脑宁胶囊、盐酸替罗非班注射用浓溶液、盐酸替罗非班氯化钠注射液、参芎葡萄糖注射液、注射用盐酸地尔硫卓、乐脉丸、注射用培美曲塞二钠、注射用盐酸吉西他滨、盐酸伊立替康注射液、注射用磷酸氟达拉滨、注射用奥沙利铂、来曲唑片、玻璃酸钠注射液（含玻璃酸钠原料药）、镇痛活络酊、通迪胶囊、骨筋丸胶囊、妇平胶囊、金鸡丸、儿童回春颗粒、注射用泮托拉唑钠、注射用奥美拉唑钠、注射用兰索拉唑、复方胆通胶囊、消炎利胆胶囊、冰栀伤痛气雾剂、注射用盐酸克林霉素磷酸酯、注射用单磷酸阿糖腺苷、注射用更昔洛韦、复方柳唑气雾剂、伏立康唑片、医用透明质酸钠凝胶、氟比洛芬酯注射液。公司手握纳米制剂、玉冠丰两大独家研发平台，榄香烯、玻璃酸钠院内集采持续放量，一边自产特色抗肿瘤长效制剂，一边承接药企 CDMO 代工，院内制剂 + 外包代工双线增收，订单常年饱满。第7名：海南海药，手握 15 亿锁定订单，供货周期直达 2027 年。海南海药股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是注射用头孢西丁钠、注射用头孢唑肟钠、注射用美罗培南、注射用氨曲南、注射用头孢呋辛钠、注射用头孢曲松钠、盐酸米诺环素胶囊、头孢克洛颗粒、头孢克洛干混悬剂、注射用头孢美唑钠、肠胃康系列（颗粒剂、片剂）、枫蓼肠胃康口服液、枫蓼肠胃康分散片、聚乙二醇4000散、富马酸伏诺拉生片、醋氨己酸锌胶囊、紫杉醇注射液、复方红豆杉胶囊、7-ANCA、4-AA、头孢西丁钠、头孢西丁酸、头孢唑肟钠、氨曲南、美罗培南、地氯雷他定口服溶液、注射用维生素C、小柴胡颗粒、红宝牌太和胶囊、双参活血通络颗粒、罗沙司他胶囊、利奈唑胺片、Crystaderm。公司走差异化路线，肝纤维化、神经领域拥有独家首创创新药，核心产品氟非尼酮获评突破性治疗品种。抗癫痫新药同步出海洽谈合作，肠胃康抗感染制剂铺满全国大小医院，院内长期采购协议稳稳兜底，属于冷门细分赛道隐形实力派。第6名：荣昌生物，45 亿大额订单交付到 2027 年末，国产稀缺双独家药企。荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC278、RC288。公司自研 ADC 药物、红斑狼疮自免新药双王牌在手，同赛道国内竞品极少，核心 ADC 完成重磅海外授权，海内外医院终端采购持续放量，海外药企合作订单不断兑现，自免赛道稀缺标的。第5名：科伦药业，68 亿订单撑到 2027 上半年，ADC 管线孵化之王。四川科伦药业股份有限公司的主营业务是输液产品及非输液医药产品的研发、生产和销售。公司的主要产品是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等。公司是国家大容量注射剂工程技术研究中心、生物靶向药物国家工程研究中心等多个国家创新平台。公司依靠成熟制剂稳定现金流，疯狂孵化差异化 ADC 管线，旗下科伦博泰多次对外授权新药，海外里程碑收益持续落袋。肿瘤靶向药顺利进医保集采放量，海内外药企管线合作源源不断，长期订单稳定释放。第4名：凯莱英，99 亿框架订单覆盖 2026 至 2028 年，多肽、ADC 高端 CDMO 稀缺龙头。凯莱英医药集团(天津)股份有限公司的主营业务是为国内外制药公司、生物技术公司提供药品全生命周期的一站式服务。公司的主要产品是小分子CDMO解决方案、新兴业务。凯莱英生物AsymBio偶联药物开发平台成功入围第12届WorldADCAwards“BestADCPlatformTechnology”奖项，印证了凯莱英生物在全球抗体偶联药物CDMO领域的卓越地位。公司手握寡核苷酸、大分子偶联高壁垒独家工艺，深度绑定全球跨国药企，多款重磅新药签订长期锁产协议，海外大额储备订单充足，CXO 细分赛道硬核心。第3名：百济神州，126 亿供货订单铺满 2026-2028 年，国产新药全球化标杆。百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是抗肿瘤类药物。上周单家接待 207 家机构调研，关注度直接拉满。搭建完整全球商业化团队，多款创新药在欧美多国获批上市，海外营收占比行业顶尖，全球医疗机构全部锁定长期供货，国产新药出海第一梯队。第2名：恒瑞医药，398 亿在手订单断层行业第一，排期直接干到 2029 年。江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。国内全品类综合创新药标杆，手握多款自主一类新药，多条 ADC 管线同步推进，频繁达成海外大额合作。国内各级医院核心供货企业，海内外长单源源不断，研发、商业化、产能三线无短板，稳稳坐稳创新药龙头王座。第1名：药明康德，590 亿在手订单排到 2027 年三季度。无锡药明康德新药开发股份有限公司的主营业务是为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务。公司的主要产品是化学业务、测试业务、生物学业务、其他业务。公司是全球独一份全链条 CRDMO 龙头。药物发现、临床前研究、临床试验、原料药生产一条龙全覆盖，服务全球数千家药企，ADC、GLP、细胞治疗项目批量落地。刚落地海外司法利好，半年报业绩大超预期，上调全年营收指引，全球长期研发订单持续扩容，业绩弹性拉满。给大家划重点：近日创新药大涨，但板块内部分化极端！那些纯蹭概念、零大额长单的小票，上涨全靠短线游资炒作；而上面八强企业，订单全部锁定未来 2-3 年业绩，就算市场短期震荡，营收利润也有实打实兜底。当前政策持续扶持生物医药，新版药品管理法加速创新药上市、医保扩容拓宽院内销量，叠加外资药企外包需求爆发，只有手握技术、产能、长单的硬核药企，才能吃到长期红利。【注意】本文所有数据均来自网络公开信息关注九九，经常点“赞”评论的朋友，可以提升活跃度，这样能在第一时间收到九九的文章！复盘文章仅作行业研究，不构成任何投资建议。投资有风险，入市需谨慎。

2026-08-09

·北京医学感染与传染研究

国际抗微生物制剂杂志 67卷 7-9期（2026年8月9日更新）

International Journal of Antimicrobial Agents Volume 67, Issue 7 国际抗微生物制剂杂志 67卷 7期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/7 1 Title Page & Editorial Board 目录与编委会 Article 107862 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息页） 2 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与信息页 Article 107845 Full Length Articles（长篇论著） 3 Targeting the human protein disulfide isomerase A3 as a broad-spectrum antiviral approach against human respiratory viruses 以人蛋白二硫键异构酶A3为靶点，开发针对人类呼吸道病毒的广谱抗病毒方法 Giulia Sibille, Arianna Maggiora, Giorgia Cimato, Anna Luganini, Giorgio Gribaudo Article 107802 4 Comparative outcomes of daptomycin and linezolid in vancomycin-resistant enterococcal intra-abdominal infections with bacteraemia 达托霉素与利奈唑胺治疗耐万古霉素肠球菌所致伴菌血症的腹腔内感染的疗效比较 Tsung-Yu Tsai, Yu-Chung Chuang, Jia-Ling Yang, Chi-Ying Lin, ... Shan-Chwen Chang Article 107792 5 Synthetic quinolone-tethered aminoguanidine derivatives exhibit potent anti-plasmodial activity 合成的喹诺酮连接氨基胍衍生物表现出强效的抗疟原虫活性 Nanang R. Ariefta, Richard M. Beteck, Lesetja J. Legoabe, Yoshifumi Nishikawa Article 107797 6 Association between antimicrobial resistance and in-hospital mortality in adults with bacterial infective endocarditis: A nationwide cohort study 抗菌药物耐药性与成人细菌性感染性心内膜炎住院死亡率之间的关联：一项全国性队列研究 Iván Oterino-Moreira, Francisco Javier Candel-González, Montserrat Pérez-Encinas, Susana Lorenzo-Martínez Article 107805 7 Machine learning-based prediction of multi-level anti-microbial resistance in Klebsiella pneumoniae using whole-genome sequencing data 基于全基因组测序数据，利用机器学习预测肺炎克雷伯菌的多层级抗菌药物耐药性 Xinmiao Jia, Jingjia Zhang, Jing Chen, Jun Wang, ... Qiwen Yang Article 107807 8 Investigating the role of novel alphatectiviruses in reducing carriage and transfer of antimicrobial resistance plasmids 新型α干扰病毒在减少耐药质粒携带和转移中的作用研究 Mattis Kreins-Irle, Michael Berger, Ágnes Solti-Hodován, Krishnendu Mukherjee, ... Ulrich Dobrindt Article 107806 9 A Multicenter, Randomized, Double-Blind, Imipenem/Cilastatin-Controlled Clinical Study of Cefiderocol for the Treatment of Complicated Urinary Tract Infections Caused by Gram-Negative Pathogens in Chinese Adults 关于头孢地尔治疗中国成人由革兰氏阴性菌引起的复杂性尿路感染的多中心、随机、双盲、以亚胺培南/西司他丁为对照的临床研究 Jinyi Yuan, Deyong Fan, Henglan Wu, Bei Jia, ... Yingyuan Zhang Article 107812 10 Multidrug-Resistant Acinetobacter baumannii Pneumonia in Clinical Therapy: A Systematic Review and Network Meta-analysis on Effectiveness and Safety of Different Antibiotic Combination Regimens 多重耐药鲍曼不动杆菌肺炎的临床治疗：不同抗生素联合用药方案有效性和安全性的系统综述与网络荟萃分析 Shao-Yuan Hao, Hau-Yu Lin, Po-I Yeh, Hui-Chuan Hsiao, ... Po-Liang Lu Article 107815 11 Population pharmacokinetics of polymyxin B in critically ill patients with multi–drug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa infections 多药耐药（MDR）鲍曼不动杆菌和铜绿假单胞菌感染危重患者中多粘菌素B的群体药代动力学 Puteri Juanita Zamri, Saskia A. Wölky, Maria P. Hernandez-Mitre, Xin Liu, ... Mohd Hafiz Abdul-Aziz Article 107816 Short Communications（短讯） 12 Model-informed cefepime dosing in paediatric patients receiving continuous renal replacement therapy 接受连续性肾脏替代治疗的儿科患者的头孢吡肟模型指导给药 Ronaldo Morales Junior, Shannon Reinert, Emily Diseroad, Erin Schuler, ... H. Rhodes Hambrick Article 107809 13 Aggressive joint pharmacokinetic/pharmacodynamic target attainment of TDM-guided continuous infusion meropenem-vaborbactam monotherapy: A valuable strategy for maximizing the microbiological outcome of documented KPC-producing Enterobacterales infections? TDM指导下美罗培南-韦博巴坦持续输注单药治疗的积极联合药代动力学/药效学目标达标：一种最大化KPC产肠杆菌科细菌感染微生物学结局的有价值策略？ Milo Gatti, Cecilia Bonazzetti, Benedetta Secci, Beatrice Giorgi, ... Federico Pea Article 107811 14 Efficacy and pharmacokinetics of a stepwise isolated phage cocktail against carbapenem-resistant Klebsiella pneumoniae in a murine pneumonia model 逐步分离噬菌体鸡尾酒疗法对抗碳青霉烯耐药肺炎克雷伯菌的疗效和药代动力学：小鼠肺炎模型研究 Xin Yin, Huan Luo, Yu Feng, Qingqing Fang, Zhiyong Zong Article 107810 15 In vivo emergence of cross-resistance to ceftazidime/avibactam and cefiderocol through selection of KPC variants in Klebsiella pneumoniae clinical isolates 肺炎克雷伯菌临床分离株通过选择KPC变异株，在体内对头孢他啶/阿维巴坦和头孢地尔产生交叉耐药性 Gabriele Bianco, Jacqueline Findlay, Sara Comini, Cristina Costa, ... Matteo Boattini Article 107808 Letters to the Editor（致编辑的信） 16 In reply to the letter to the editor regarding “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis” 回复致编辑关于“治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析”的来信 Itay Zahavi, Digbijay Kunwar, Judit Olchowski, Hagar Dallasheh, Mical Paul Article 107800 17 Comment on “Enhancing meropenem therapy in critical care: A retrospective study of PK/PD target attainment and therapeutic drug monitoring” 对“加强重症监护病房美罗培南治疗：一项关于药代动力学/药效学目标达成情况和治疗药物监测的回顾性研究”的评论 Xuefeng Yu Article 107804 18 Analytical feasibility of linezolid quantification by LC–MS/MS using dried plasma spot microsampling 采用干血浆斑微量采样法通过液相色谱-串联质谱（LC–MS/MS）技术定量测定利奈唑胺的分析可行性研究 Anisa Bardhi, Bochra Mansour, Dimitri Schlemmer, Pascal Robidou, ... Noël Zahr Article 107799 19 Beyond parasite clearance: Three unresolved methodological challenges in cross-regional PKDL trials 突破寄生虫清除：跨区域皮肤型黑热病（PKDL）试验中三个尚未解决的方法学挑战 Ciyu Zhao, Shanshan Yuan Article 107798 20 Comment on “Nanomedicine for phage therapy: Encapsulation strategies for enhanced antimicrobial efficacy” 对"噬菌体治疗的纳米医学：增强抗菌疗效的包封策略"的评论 Wenhao Wang, Ziyu Zhao, Zhengwei Huang Article 107814 21 Comment on “ESBL-producing Escherichia coli bacteremic urinary tract infections: Clinical and economic burden and antimicrobial stewardship opportunities in a retrospective cohort study” 对"产ESBL大肠埃希菌血源性尿路感染：一项回顾性队列研究中的临床和经济负担及抗菌药物管理机会"的评论 Neeraj Singh, Monika Srivastav Article 107820 International Journal of Antimicrobial Agents Volume 67, Issue 8 国际抗微生物制剂杂志 67卷 8期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/8 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息页） 1 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与信息页 Article 107873 Reviews（综述） 2 Comparative efficacy and safety of antifungal prophylactic agents in allogeneic hematopoietic stem cell transplantation: A systematic review and network meta-analysis 异基因造血干细胞移植中抗真菌预防药物的疗效和安全性比较：系统综述与网络荟萃分析 Xinyi Li, Ruonan Shao, Tingting Zhang, Yuping Fan, ... Sizhou Feng Article 107826 3 Revisiting fluoroquinolone prophylaxis in haematological malignancies and hematopoietic cell transplantation: A decade of evidence and gaps in understanding the impact of gut colonization with fluoroquinolone-resistant Enterobacterales 重新审视血液系统恶性肿瘤和造血干细胞移植中氟喹诺酮类药物的预防应用：十年证据及对氟喹诺酮耐药肠杆菌目细菌肠道定植影响的认知空白 Hilal Abdessamad, Dania Abdallah, Rana Attieh, Shadi Eid, ... Rima Moghnieh Article 107824 Full Length Articles（长篇论著） 4 Multi-target modulation of the AKT/NF-κB signalling axis by quercetin attenuates Stenotrophomonas maltophilia-induced pneumonia 槲皮素对AKT/NF-κB信号轴的多靶点调节可减轻嗜麦芽寡养单胞菌诱导的肺炎 Hanzhao Zhang, Yang Li, Fuming You, Jiang Li, ... Luomeng Chao Article 107823 5 Risk factors and serum concentration thresholds associated with tigecycline-induced hepatotoxicity in critically ill patients 危重患者替加环素诱导肝毒性的相关风险因素和血清浓度阈值 Mengxue Li, Jie He, Gaoqiu Dong, Hua Shao, Linlin Hu Article 107822 6 Population Pharmacokinetics of Total and Free Ceftriaxone in Critically Ill and Non-Critically Ill Hospitalised Adult Patients 危重与非危重住院成年患者中总头孢曲松和游离头孢曲松的群体药代动力学 Eko Setiawan, Alvaro Gonzalez, Saskia A. Wölky, Menino Osbert Cotta, ... Mohd H. Abdul-Aziz Article 107817 7 Stepwise within-host evolution of a blaCTX-M-27-positive Klebsiella pneumoniae clone under changing antimicrobial pressures leading to enhancement of β-lactam resistance 在不断变化的抗菌压力下，blaCTX-M-27阳性肺炎克雷伯菌克隆的宿主体内逐步进化及其β-内酰胺耐药性增强 Masamune Aihara, Yasuhiro Gotoh, Keiji Nakamura, Tomoko Kimura-Hyoda, ... Tetsuya Hayashi Article 107840 8 Integrated prediction of ceftriaxone resistance in major Salmonella serotypes using MALDI-TOF MS data with balanced datasets and machine learning 利用MALDI-TOF MS数据结合平衡数据集与机器学习对主要沙门菌血清型头孢曲松耐药性的整合预测 Jun Ren, Jintao Xia, Mengyu Zhang, Chunhong Liu, ... Wenjun Cao Article 107832 9 The ATP-binding cassette transporter CstA as a novel therapeutic target for treating carbapenem-resistant Enterobacteriaceae bacteria ATP结合盒转运蛋白CstA作为治疗碳青霉烯耐药肠杆菌科细菌的新型治疗靶点 Jiafang Fu, Rong Wang, Yayu Liu, Gongli Zong, ... Guangxiang Cao Article 107837 10 Characterization and host range associating factors of Staphylococcus aureus bacteriophage PBSA08; Using Australian MRSA reference set 葡萄球菌噬菌体PBSA08的特征及宿主范围相关因子分析：基于澳大利亚MRSA参考菌株集 Shinwon Lee, Stephanie Lynch, Clare Fisher, Nouri Ben Zakour, ... Jonathan R. Iredell Article 107838 11 In vivo evolution of tigecycline resistance in ST540 carbapenem-resistant Acinetobacter baumannii: Mechanisms and global epidemiological perspective ST540碳青霉烯耐药鲍曼不动杆菌体内替加环素耐药性进化：机制与全球流行病学视角 Jintao He, Hanqi Zhang, Haiyang Liu, Wanxun Lin, ... Chuanxin Yang Article 107841 12 Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial 在伴有神经精神共病的HIV感染者中，改用比克替拉韦/恩曲他滨/丙酚替诺福韦对比继续使用多替拉韦/拉米夫定的安全性和耐受性：来自INSTI相关神经精神障碍管理（MIND）临床试验的第24周和第48周结果 Ignacio Perez-Valero, Diana Corona Mata, María Jose Crussells Canales, Maria Velasco Arribas, ... Antonio Rivero Article 107825 13 Comparative genomic surveillance of fluoroquinolone resistance markers across major riverine hotspots by leveraging public metagenomes 利用公共宏基因组对主要河流热点区域氟喹诺酮耐药标志物开展基因组监测比较 Kheerthana Ramesh, Padmanaban Velayudhaperumal Chellam Article 107839 14 Impact of cefiderocol on Klebsiella pneumoniae: A population-based longitudinal analysis of phenotypic and genotypic responses at subinhibitory and inhibitory concentrations 头孢地尔对肺炎克雷伯菌的影响：基于群体的亚抑菌浓度与抑菌浓度下表型及基因型应答的纵向分析 German M. Traglia, Samyar Moheb, Usman Akhar, Cecilia Quiroga, ... Maria Soledad Ramirez Article 107844 Short Communications（短讯） 15 The need for systematic therapeutic drug monitoring of isoniazid in tuberculosis: A real-world study. 结核病中异烟肼的系统性治疗药物监测需求：一项现实研究。 Marine Chancel, Youssef Bennis, Sandra Bodeau, Anne-Sophie Lemaire-Hurtel, ... Claire Andréjak Article 107827 16 Multidrug-resistant Enterobacterales in United States hospitals: Frequency and susceptibility to newer β-lactamase inhibitor combinations (2020–2024) 美国医院中多重耐药肠杆菌目细菌的发生频率及对新型β-内酰胺酶抑制剂复合制剂的敏感性（2020–2024） Helio S. Sader, Rodrigo E. Mendes, John H. Kimbrough, Marisa L. Winkler, Mariana Castanheira Article 107835 17 Environmental surveillance in Chile reveals a multidrug-resistant Salmonella Amager from an emerging blaCTX-M-65/pESI-positive lineage 智利环境监测发现来源于新兴blaCTX-M-65/pESI阳性谱系的多重耐药阿马格沙门菌 Josefina Miranda-Riveros, Daniel Tichy-Navarro, María José Navarrete, Angélica Reyes-Jara, ... Alejandro Piña-Iturbe Article 107831 Letters to the Editor（致编辑的信） 18 Comment on: New-generation antibiotics and nonantibiotic strategies against carbapenemase-producing Enterobacterales: More focus on metallo-β-lactamase producers 评论：新一代抗生素及非抗生素策略对抗产碳青霉烯酶肠杆菌目细菌：重点关注金属β-内酰胺酶生产者 Xiaopei Yang, Wen Zhou, Xisong Ke Article 107833 19 Comment on “Present trajectories to forecasted future: A longitudinal analysis of hospital antibiotic use in China from 2013 to 2024 and projections to 2030” 评论"当前轨迹与未来预测：中国医院抗生素使用的纵向分析（2013–2024）及至2030年的预测" Jiaxin Luo Article 107821 20 In reply to the letter to editor regarding ``Enhancing meropenem therapy in critical care: A retrospective study of PK/PD target attainment and therapeutic drug monitoring'' 关于"增强重症监护中美罗培南治疗：PK/PD靶标达成率与治疗药物监测的回顾性研究"致编辑信的回复 Jingli Liao, Chao Li, Jingxian Liu, Wei Wu, ... Lixia Li Article 107830 21 Reply to the letter to the editor regarding “Beneficial effects of a compound probiotic in Helicobacter pylori-infected patients aged over 40 years: An open-label randomised clinical trial” 关于"复合益生菌对40岁以上幽门螺杆菌感染患者的有益作用：一项开放标签随机临床试验"致编辑信的回复 Chenghai Yang, Jie Cheng, Meng Zhang, Wenyi Zhang, Ye Chen Article 107836 22 Comment on “Disrupting bacterial metabolism by targeting LDH reverses aminoglycoside resistance in Streptococcus suis”: Methodological and translational considerations 评论"通过靶向LDH干扰细菌代谢可逆转猪链球菌氨基糖苷类耐药性"：方法学与转化方面的考量 Jiehua Han Article 107834 23 Targeted use of sulopenem in multidrug-resistant uncomplicated urinary tract infections sulopenem在多重耐药非复杂性尿路感染中的靶向应用 Areej Riaz, Raana Riaz Article 107828 International Journal of Antimicrobial Agents Volume 67, Issue 9 国际抗微生物制剂杂志 67卷 9期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/9 1. Title Page & Editorial Board 目录及编者按 Article 107939 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息页） 2. International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与信息页 Article 107899 Editor's Choice（编辑推荐） 3. Co-occurrence of carbapenem and tigecycline resistance genes in ST1545 Klebsiella pneumoniae clinical isolates from China 中国 ST1545 型临床分离肺炎克雷伯菌中碳青霉烯类与替加环素耐药基因的共存情况 Junwei Huang, Xiaoyu Lu, Jing Xiang, Qiaojun Wang, ... Ruichao Li Article 107856 Hot Topic（热点议题） 4. Surveys on phage therapy: Current understanding and practical implications 噬菌体疗法调查：当前认识与实践意义 Maciej Żaczek, Andrzej Górski, Beata Weber-Dąbrowska, Marzanna Łusiak-Szelachowska, ... Ryszard Międzybrodzki Article 107880 Remembering Prof Geddes（缅怀盖迪斯教授） 5. Professor Alasdair Macintosh Geddes: A life of science, service, and kindness 阿拉斯代尔·麦金托什·盖迪斯教授：一生投身科研、济世行医、温厚待人 Stefania Stefani, Athanasios Tsakris Article 107878 Reviews（综述） 6. Wild-type MIC distributions and epidemiological cut-off values for ibrexafungerp, manogepix, and rezafungin against WHO fungal priority pathogens 伊布雷沙芬净、马诺吉匹和雷扎芬净对WHO真菌优先病原体的野生型MIC分布及流行病学折点值 Maria J. Morelo, Carolina Firacative, Guillermo Garcia-Effron, Beatriz L. Gómez, Andres Ceballos-Garzon Article 107870 7. Burden and global distribution of antimicrobial resistance in non-bloodstream infections among adults with cirrhosis: A systematic review and proportional meta-analysis 肝硬化成人非血流感染中抗菌药物耐药性的负担与全球分布：系统综述与比例荟萃分析 Cansu Ozdemir, Tuhin Paul, Kasope Egoh, Joseph J. Wanford, ... Ellis K. Paintsil Article 107849 8. The efficacy and safety of inhaled antibiotics in the treatment of lower respiratory tract infection: An updated meta-analysis and evidence map of systematic reviews 吸入性抗生素治疗下呼吸道感染的有效性和安全性：一项更新的荟萃分析及系统综述证据图谱 Yuanhui Hu, Sha Diao, Hailong Li, Linan Zeng, ... Lingli Zhang Article 107872 9. Aztreonam-avibactam for Carbapenem-resistant gram-negative infections: Mechanisms, clinical efficacy, the challenge of resistance and susceptibility testing 氨曲南-阿维巴坦用于耐碳青霉烯类革兰阴性菌感染：作用机制、临床疗效、耐药挑战及药敏检测 Fangting He, Xian Zhang, Haiyan Ye, Jun Luo, Yao Wang Article 107861 Full Length Articles（长篇论著） 10. Antibacterial efficacy of a broad lytic spectrum phage against Salmonella in different food matrices and broilers 广谱裂解噬菌体对不同食品基质和肉鸡中沙门氏菌的抗菌效果 Pei Li, Xin Wang, Jianan Liu, Zhuojun Li, ... Wei Zhang Article 107843 11. Development and application of a CNS PBPK model that integrates CSF dynamics to optimize dosing regimens of antibacterial agents in pediatric patients with meningitis 整合脑脊液动力学的中枢神经系统PBPK模型的开发与应用：优化儿童脑膜炎患者抗菌药物给药方案 Chaozhuang Shen, Yi Zheng, Bing Liu, Yue-E Wu, ... Wei Zhao Article 107857 12. The costs and health outcomes associated with a personalised antibiotic combination testing service for carbapenem-resistant Pseudomonas aeruginosa: A cost-effectiveness analysis 针对碳青霉烯耐药铜绿假单胞菌的个体化抗菌药物联合药敏检测服务的成本与健康结局：成本效益分析 Yiying Cai, Tze-Peng Lim, Winnie Lee, Jocelyn Q. Teo, ... Nicholas Graves Article 107852 13. Emergence of dalbavancin non-susceptible methicillin-resistant Staphylococcus epidermidis (MRSE) in a patient treated with dalbavancin prolonged therapy: Case report, therapeutic drug monitoring and genomic characterization 达巴万星长疗程治疗中出现达巴万星不敏感甲氧西林耐药表皮葡萄球菌（MRSE）病例报告：治疗药物监测与基因组特征分析 Simone Giuliano, PierGiorgio Cojutti, Michela Bulfoni, Marco Cotrufo, ... Paolo Gaibani Article 107877 14. Droplet digital PCR assay for simultaneous detection of the ERG11 mutation and copy number variation associated with azole resistance in Candida tropicalis 液滴数字PCR法同步检测热带念珠菌中与唑类耐药相关的ERG11突变及拷贝数变异 Xin Fan, Nan Wang, Xi Chen, Chianru Tan, ... Meng Xiao Article 107847 15. A novel peptide mR63-77 from Rpl36 protein showing potent antibacterial activities 来源于Rpl36蛋白的新型肽mR63-77展现强效抗菌活性 Longxiao Liu, Xue Liu, Mengqi Jiang, Jingli Wang, ... Xia Wang Article 107865 16. Chromosomal integration of virulence plasmid fragments in a Carbapenem-resistant hypervirulent Klebsiella pneumoniae sequence type 2237 耐碳青霉烯高毒力肺炎克雷伯菌序列型2237中毒力质粒片段的染色体整合 Donghong Yang, Shuaihua Fan, Han Jia, Ying Shang, ... Pengcheng Du Article 107869 17. Antifungal and immunomodulatory activities of dihydroartemisinin-loaded chitosan nanoparticles against fluconazole‑resistant Candida tropicalis 双氢青蒿素壳聚糖纳米颗粒对氟康唑耐药热带假丝酵母的抗真菌和免疫调节活性 Min Yang, Yan Liu, Kunyu Xu, Peike Wang, ... Qingbi Zhang Article 107875 18. The role of gametocytogenesis in the spread of resistance to artemisinin-based combination therapies 配子体形成在青蒿素类复方疗法耐药性传播中的作用 Kristan Alexander Schneider, Kanika Verma, Anil Verma, George Kamanga, Praveen Kumar Bharti Article 107868 19. Exploratory study on colistin sulfate pharmacokinetics and safety in critically ill elderly patients 硫酸黏菌素在危重老年患者体内药代动力学与安全性探索性研究 Aochao Xu, Xiaomiao Xiong, Na Zhang, Geping Qu, ... Yun Cai Article 107884 Short Communications（短篇评论） 20. Essential role of the leucine-293 for the AmpC β-lactamase in the resistance to cefepime, cefiderocol, and new β-lactams/β-lactamase inhibitor combinations in Enterobacter hormaechei 亮氨酸-293对蜂房哈夫尼菌AmpC β-内酰胺酶在头孢吡肟、头孢地尔及新型β-内酰胺/β-内酰胺酶抑制剂组合中耐药性的关键作用 Marta Rodríguez-Rodríguez, Enrique Alanís-Domínguez, Carlos S. Casimiro-Soriguer, José Manuel Ortiz de la Rosa, ... Ángel Rodríguez-Villodres Article 107848 21. Characterization of a novel mosaic-like mtr operon and inter-regional transmission of dual-resistant Neisseria gonorrhoeae ST7363 sub-lineage in China 中国新型嵌合样mtr操纵子表征及双重耐药淋病奈瑟菌ST7363亚谱系的跨区域传播 Bangyong Zhu, Di Wang, Chi Zhang, Yang Yang, ... Junping Peng Article 107858 22. Isavuconazole prophylaxis and treatment in pediatric HSCT recipients: Pharmacokinetics, safety, and efficacy 艾沙康唑在儿童造血干细胞移植受者中的预防与治疗应用：药代动力学、安全性及疗效 Hao Jiang, Lixiao Cai, Ningning Chen, Pan Zhang, ... Jun Yang Article 107874 23. Prospective evaluation of therapeutic target attainment with a beta-lactam dosing nomogram in critically ill adult patients 使用β-内酰胺给药列线图对危重成人患者治疗达标的前瞻性评估 Paul Williams, Menino Osbert Cotta, Mohd H. Abdul-Aziz, Kathryn Wilks, ... Jason A. Roberts Article 107883 24. Amoxicillin bone penetration in patients with medication-related osteonecrosis of the jaw: A preliminary study 阿莫西林对药物相关性颌骨坏死患者骨穿透作用的初步研究 Jessica Cusato, Alessandra Manca, Virginia Moscone, Miriam Antonucci, ... Francesco Erovigni Article 107866 25. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacterales bacteraemia in high-risk neutropenic patients in haematology: A multicentre retrospective study 血液科高危中性粒细胞减少患者产超广谱β-内酰胺酶肠杆菌血症的危险因素及预后：一项多中心回顾性研究 William Lars, Benjamin Gaborit, Anne Coste, Amandine Le Bourgeois, ... Raphaël Paret Article 107882 Letters to the Editor（致编辑的信） 26. Delafloxacin-induced fever in a patient with staphylococcal periprosthetic joint infection 葡萄球菌性假体周围关节感染患者使用德拉沙星后出现发热 Manuela Sanz de Mena, Daniel Pérez Prieto, Albert Alier Fabrego, Sonia Luque, Joan Gómez-Junyent Article 107842 27. Comment on “Antibiotic susceptibility of Gram-negative bacteria in cerebrospinal fluid compared with Mueller-Hinton broth and artificial cerebrospinal fluid” 对"脑脊液中革兰阴性菌抗菌药物敏感性与Mueller-Hinton肉汤及人工脑脊液的比较"一文的评论 Tomefa E. Asempa Article 107860 28. In reply to the Letter to the Editor ``Antibiotic susceptibility of Gram-negative bacteria in cerebrospinal fluid compared to Mueller-Hinton broth and artificial cerebrospinal fluid,'' Int J Antimicrob Agents. 2026 Apr;67(4):107730 回复致编辑的信《脑脊液与Mueller-Hinton肉汤及人工脑脊液中革兰阴性菌的抗生素敏感性比较》，《国际抗菌药物杂志》，2026年4月；67(4):107730 Jana Seele, Utz Reichard, Roland Nau Article 107867 29. Comment on “Risk factors and serum concentration thresholds associated with tigecycline-induced hepatotoxicity in critically ill patients” 关于"危重患者替加环素诱导肝毒性的危险因素及血清浓度阈值"的评论 Deepti M. Sati, Vanashri Dhananjay Shinde, Chhaya Agarwal Article 107846 30. Comment on “Development and validation of a predictive model for profiling antibiotic resistance phenotypes of Acinetobacter baumannii strains via clinical MALDI-TOF mass spectra: A multicentre study” 关于"通过临床MALDI-TOF质谱图谱对鲍曼不动杆菌耐药表型进行预测建模：一项多中心研究"的评论 Patil Saurabh Shrirang, Priyanka Bansal, Vikrant Abbot, Shitharth Sharma Article 107851 31. Clinical and epidemiological factors fail to predict NDM-5–producing Escherichia colibloodstream infections among MBL-producing Enterobacterales 临床和流行病学因素无法预测产金属β-内酰胺酶（MBL）肠杆菌科细菌中产 NDM-5 型新德里金属 β- 内酰胺酶大肠埃希菌血流感染 Benoît Pilmis, Laurent Dortet Article 107850 32. Letter to the editor: Comment on “Amphotericin B ameliorates obesity through modulating gut mycobiome dysbiosis and brown adipose tissue thermogenesis in high-fat diet-induced mice” 致编辑的信：对《两性霉素B通过调节高脂饮食诱导小鼠肠道真菌菌群失调与棕色脂肪产热改善肥胖》一文的述评 Yike Liu Article 107876 Corrigendum（勘误） 33. Corrigendum to “Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination” [International Journal of Antimicrobial Agents, 57 (2021) 106277] 勘误：《大鼠阴道菌群失调可通过阴道菌群移植或益生菌复合制剂有效修复》（刊载于《国际抗菌药物杂志》，2021 年第 57 卷，文章编号106277） Tingtao Chen, Chaofei Xia, Hong Hu, Huan Wang, ... Hong-Bo Xin Article 107891

微生物疗法临床1期

100 项与氨曲南相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00240	氨曲南	J01DF01	DB00355

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
囊性纤维化	美国	Gilead Sciences, Inc.	2010-02-22
细菌感染	美国	Laboratoires Delbert SAS	2008-01-22
革兰氏阴性菌感染	中国	中美上海施贵宝制药有限公司	1997-01-01
腹腔感染	美国	Laboratoires Delbert SAS	1996-11-01
脑膜炎	日本	Eisai Co., Ltd.	1988-05-31
脑膜炎	日本	Meiji Seika Pharma Co., Ltd.	1988-05-31
腹腔脓肿	日本	Meiji Seika Pharma Co., Ltd.	1987-01-12
腹腔脓肿	日本	Eisai Co., Ltd.	1987-01-12
胆管炎	日本	Meiji Seika Pharma Co., Ltd.	1987-01-12
胆管炎	日本	Eisai Co., Ltd.	1987-01-12
胆囊炎	日本	Eisai Co., Ltd.	1987-01-12
胆囊炎	日本	Meiji Seika Pharma Co., Ltd.	1987-01-12
膀胱炎	日本	Eisai Co., Ltd.	1987-01-12
膀胱炎	日本	Meiji Seika Pharma Co., Ltd.	1987-01-12
出血性败血症	日本	Meiji Seika Pharma Co., Ltd.	1987-01-12
出血性败血症	日本	Eisai Co., Ltd.	1987-01-12
子宫内感染	日本	Eisai Co., Ltd.	1987-01-12
子宫内感染	日本	Meiji Seika Pharma Co., Ltd.	1987-01-12
角膜炎	日本	Meiji Seika Pharma Co., Ltd.	1987-01-12
角膜炎	日本	Eisai Co., Ltd.	1987-01-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
耐碳青霉烯类细菌感染	临床3期	美国	Meiji Seika Pharma Co., Ltd.	2023-09-22
耐碳青霉烯类细菌感染	临床3期	中国	Meiji Seika Pharma Co., Ltd.	2023-09-22
耐碳青霉烯类细菌感染	临床3期	日本	Meiji Seika Pharma Co., Ltd.	2023-09-22
耐碳青霉烯类细菌感染	临床3期	克罗地亚	Meiji Seika Pharma Co., Ltd.	2023-09-22
耐碳青霉烯类细菌感染	临床3期	捷克	Meiji Seika Pharma Co., Ltd.	2023-09-22
耐碳青霉烯类细菌感染	临床3期	法国	Meiji Seika Pharma Co., Ltd.	2023-09-22
耐碳青霉烯类细菌感染	临床3期	希腊	Meiji Seika Pharma Co., Ltd.	2023-09-22
耐碳青霉烯类细菌感染	临床3期	以色列	Meiji Seika Pharma Co., Ltd.	2023-09-22
耐碳青霉烯类细菌感染	临床3期	拉脱维亚	Meiji Seika Pharma Co., Ltd.	2023-09-22
耐碳青霉烯类细菌感染	临床3期	斯洛伐克	Meiji Seika Pharma Co., Ltd.	2023-09-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05887908 (Integral-1, Pubmed \| Lancet)	临床3期	急性肾盂肾炎 \| 复杂的尿路感染	614	Cefepime-nacubactam	繭膚壓齋憲積窪鹽齋窪(網鑰觸鏇繭鑰遞繭艱積) = 鏇鹹壓顧醖蓋膚鹽繭網網廠製夢繭淵衊鹹鏇鹽 (選醖網艱膚衊廠衊窪簾 ) 更多	积极	2026-05-01
NCT05887908 (Integral-1, Pubmed \| Lancet)	临床3期	急性肾盂肾炎 \| 复杂的尿路感染	614	Aztreonam-nacubactam	繭膚壓齋憲積窪鹽齋窪(網鑰觸鏇繭鑰遞繭艱積) = 鑰遞窪簾衊淵淵夢餘遞網廠製夢繭淵衊鹹鏇鹽 (選醖網艱膚衊廠衊窪簾 ) 更多	积极	2026-05-01
NCT05887908 (Integral-1, CTgov)	临床3期	急性肾盂肾炎 \| 外胚层发育不良 \| 复杂的尿路感染	614	imipenem/cilastatin	鹽壓窪簾襯憲簾顧築獵 = 窪鬱醖餘願獵淵壓觸築壓顧齋衊鹽製網艱鑰衊 (膚膚醖醖淵網繭鹽夢願, 廠壓範選鹹獵積憲壓蓋 ~ 淵顧衊選夢襯選鏇艱醖) 更多	-	2025-11-25
NCT03978091 (Pubmed) 人工标引	临床1期	-	19	Aztreonam+Ceftazidime+Avibactam	壓選餘積築餘觸廠壓糧(艱鏇淵繭夢餘構夢鑰顧) = 積遞憲膚製憲簾繭遞鏇積艱製簾蓋艱網願願夢 (膚鹽廠觸鹽顧鏇鹽鑰壓 ) 更多	积极	2022-11-17
NCT03867734 (CTgov)	临床2/3期	淋病 \| 淋菌性尿道炎 \| 咽疾病	32	Aztreonam	糧選觸襯襯膚醖願顧構(鑰齋範製窪鑰齋艱積壓) = 膚蓋獵蓋齋選構淵餘顧廠鏇顧糧餘願餘觸繭窪 (獵壓壓觸構構餘蓋構選, 衊壓鹽鏇醖窪遞鹽壓顧 ~ 築憲製製艱積鑰遞醖衊) 更多	-	2022-01-06
NCT03978091 (CTgov)	临床1/2期	细菌感染	48	AVYCAZ IV (AVYCAZ IV)	憲觸膚餘鹹獵築鬱顧製 = 積製鏇窪鏇築願鬱獵蓋網積製夢壓鬱簾糧窪鏇 (鹹鹹廠淵築衊鑰淵窪鹽, 憲齋鑰廠鏇鏇顧餘鬱廠 ~ 鹹淵願築糧醖艱憲築窪) 更多	-	2021-12-23
NCT03978091 (CTgov)	临床1/2期	细菌感染	48	AVYCAZ (AVYCAZ CI)	憲觸膚餘鹹獵築鬱顧製 = 膚獵觸積獵鹽構獵壓鹹網積製夢壓鬱簾糧窪鏇 (鹹鹹廠淵築衊鑰淵窪鹽, 選壓鏇積餘範艱壓鏇繭 ~ 選窪鏇餘選製齋艱膚窪) 更多	-	2021-12-23
NCT03158116 (A-PACT, CTgov)	临床4期	感染	5	Inhaled Aztreonam	醖窪鬱膚襯艱壓簾鏇積 = 淵衊襯積艱鑰鑰夢壓範鏇糧廠構窪蓋遞鹽蓋窪 (選獵觸衊獵廠鏇窪衊壓, 膚蓋遞蓋壓壓膚壓鏇鬱 ~ 鬱艱繭窪顧鏇鹽鹽襯遞) 更多	-	2021-07-30
NCT02730793 (CTgov)	临床2期	鼻部疾病 \| 囊性纤维化	5	Nasal Placebo+Oral Aztreonam (Standard Therapy)	淵鹹壓蓋夢網窪網鏇衊(憲憲憲鏇獵簾顧壓繭衊) = 築衊蓋蓋夢廠醖網繭觸鑰製選選淵積鑰壓蓋觸 (膚範鑰遞廠顧襯繭鹽憲, 網壓蓋遞築願夢夢壓壓 ~ 糧鏇願獵齋憲醖願齋鏇) 更多	-	2021-01-12
NCT02730793 (CTgov)	临床2期	鼻部疾病 \| 囊性纤维化	5	Oral Aztreonam (Study Therapy)	淵鹹壓蓋夢網窪網鏇衊(憲憲憲鏇獵簾顧壓繭衊) = 範觸鏇艱鹹網選顧範窪鑰製選選淵積鑰壓蓋觸 (膚範鑰遞廠顧襯繭鹽憲, 簾積築淵襯選範簾製憲 ~ 襯壓範淵願選艱蓋艱衊) 更多	-	2021-01-12
NCT03867734 (Pubmed \| Antimicrob Agents Chemother)	临床2/3期	淋病	32	Aztreonam 2g	製鬱獵築範窪鹹觸鏇衊(膚憲醖衊積範築夢淵鹹) = 鑰積糧廠憲憲醖鏇構襯衊獵憲廠齋齋憲顧鹹糧 (壓醖齋窪觸繭鬱艱顧廠 ) 更多	-	2020-12-16
NCT01659866 (CTgov)	临床4期	感染	563	Ciprofloxacin (Cipro-susceptible)	遞壓醖鹹廠鏇壓網網鹽 = 製壓鬱簾鏇膚廠齋醖範夢鬱壓鏇夢鹹糧鬱繭餘 (範餘繭築廠願廠範糧窪, 獵獵鑰鑰鬱觸襯獵鑰簾 ~ 範遞築範醖選膚積獵顧) 更多	-	2019-06-25
NCT01659866 (CTgov)	临床4期	感染	563	imipenem+aztreonam+trimethoprim-sulfamethoxazole+cefuroxime+gentamicin+ceftriaxone+amikacin (Cipro-resistant)	遞壓醖鹹廠鏇壓網網鹽 = 製醖膚夢願鹹範鏇鹽壓夢鬱壓鏇夢鹹糧鬱繭餘 (範餘繭築廠願廠範糧窪, 襯鹽願蓋鏇鹽鹽鑰鏇構 ~ 選艱構淵淵衊鑰願顧鬱) 更多	-	2019-06-25
NCT01375049 (ALPINE, Pubmed \| J Cyst Fibros)	临床2期	囊性纤维化	105	Aztreonam for inhalation solution (AZLI) 75 mg	艱襯淵憲鏇顧憲蓋醖廠(膚淵糧獵願淵衊網鑰窪) = 夢鏇夢積壓願醖繭繭觸網齋餘顧鏇願網選製顧 (繭獵繭鹽鏇齋範蓋鹹蓋 )	-	2015-01-01